Objective: The present study aimed to clarify the clinicopathological features, including the level of p53 protein expression and BRCA mutations, of primary fallopian tube cancer (PFTC) in Japanese women. Methods: A multicenter clinical survey was conducted at three Japanese institutions. Clinical data in patients with PFTC between 1998 and 2016 were collected. Immunohistochemical staining of p53 and BRCA mutation analysis by exome sequence using paraffin-embedded surgical resected specimens were performed. Results: A total of 40 patients with PFTC were enrolled in the study. The median age was 58 years (range: 38-78 years); 31 patients were menopausal. Thirty-four (85.0%) patients were diagnosed with serous adenocarcinoma (high grade, 33; low grade, 1). PFTC was classified into ampulla type, fimbriae type and undeterminable type by tumor-occupying lesion; ampulla type and fimbriae type occurred with the same frequency. Among 30 patients with high-grade serous adenocarcinoma, 6 patients showed germline mutations of BRCA1 (stop-gain 4 and frameshift deletion 2) and 2 patients showed germline mutation of BRCA2 (stop-gain 1 and frameshift deletion 1). However, only 1 patient had familial history of breast or ovarian cancer. Patients with BRCA mutations in the germline were frequently observed in ampulla type and FIGO stage I/II cancers, but no significant difference in the frequency of p53 overexpression and overall survival was observed. Conclusions: Among Japanese patients with PFTC, 26.7% presented with BRCA mutations in the germline. Additionally, p53 was important for the carcinogenesis in fallopian tubes, independent of the specific BRCA mutation.
Introduction
Primary fallopian tube cancer (PFTC) has been clinically managed as a Müllerian carcinoma with primary peritoneal cancer and primary epithelial ovarian cancer. Recent studies have identified the fimbriae of the fallopian tube as an origin of primary epithelial ovarian cancer (1, 2) , especially in patients with hereditary breast and ovarian cancer (HBOC) caused by germline BRCA1 or BRCA2 mutations (3, 4) . However, the finding that primary epithelial ovarian cancer originates in fimbriae of the fallopian tube cannot explain why primary epithelial ovarian cancer occurs at a frequency almost 50 times higher than that of PFTC (5, 6) . Moreover, the frequency of BRCA1 and BRCA2 mutations in Japanese patients with PFTC is still unknown. Therefore, we conducted a multicenter study to evaluate the clinicopathological features of PFTC, including the level of p53 protein expression and frequency of BRCA1 and BRCA2 mutations using surgically resected, formalin-fixed, paraffin-embedded specimens (FFPE).
Materials and methods
We retrospectively obtained the clinical data of patients with histologically diagnosed PFTC between October 1998 and December 2016 at three participating Japanese institutions. We restricted our analysis to macroscopic fallopian cancer and diagnosed ovarian disease only when accompanied by microscopic metastases. The following data were obtained: patient age, parity, menstrual status, preoperative value of CA125, preoperative results of endometrial cytology, date of primary surgery, site of tumor, maximum diameter of residual tumor, macroscopic photo of surgically resected specimens, histopathological diagnosis, stage according to the International Federation of Gynecology and Obstetrics (FIGO 2014), indication of postoperative chemotherapy, last follow-up period and prognosis. At least three hematoxylin-eosin (HE)-stained and -unstained histopathological specimens, including both ampulla and fimbriae, were evaluated to confirm the pathological diagnosis; immunohistochemical staining for p53 expression was then performed on the specimens. Immunohistochemical staining for p53 was performed using the automated BMK iVEW DAB Paraffin procedure on a BenchMark GX IHC/ISH Staining Module (Ventana Medical Systems Inc., Tucson, AZ, USA). Deparaffinized samples were incubated with an anti-p53 antibody (DO7, DAKO, Santa Clara, CA, USA), and positivity was determined according to the criteria used in our previous study (7) . DNA extraction and exome sequencing for analysis of BRCA1 and BRCA2 were performed on 30 cases of high-grade serous adenocarcinoma according as described previously (8) . Briefly, after a pathologist reviewed the HE-stained specimens for confirmation of the area of cancerous tissue with the histopathological diagnosis and to select noncancerous tissue, genomic DNA was extracted with a GeneRead DNA FFPE Kit (Qiagen, Germany) following the manufacturer's instructions from FFPE. In the present study, we determined the presence of germline mutations, if the same frameshift insertion or deletion, stop-gain or stop-loss (9) were confirmed in both cancerous and noncancerous tissues.
For the statistical analysis, we performed t-test, analysis of variance, Fisher's exact test and log-rank test using R software (version 3.3, R Foundation for Statistical Computing, Vienna, Austria). A P value of <0.05 was considered statistically significant. The present survey, including p53 staining and mutation analysis of BRCA1 and BRCA2 using surgically resected FFPE, was approved by the Ethics Committee of Tohoku University Hospital and each participating institution.
Results
A total of 40 patients with PFTCs were enrolled into this survey. The median patient age was 58 years (range: 38-78 years), and 77.5% of patients were menopausal. Endometrial cytology revealed malignant cells in 16.7% of the patients, and the median preoperative CA125 value was 355.1 U/ml (range: 3-9735 U/ml). Among the patients, 34 (85.0%) had serous carcinoma (high grade, 33; low grade, 1). Although FIGO stage III disease was most frequently observed, 21 patients achieved complete surgical resection. Moreover, a total of seven patients (17.5%) had family history of HBOC cancer with pancreatic cancer, endometrial cancer, breast cancer and leukemia in a first-or second-degree relative ( Table 1 ). The median survival duration of all enrolled patients was 6.5 years. Interestingly, PFTCs were classified according to the macroscopic findings of surgically resected specimens and microscopic findings of HE-stained specimens as ampulla type (main tumor occupying the ampulla with or without confirmed microscopic invasion of the fimbriae, Fig. 1 ), fimbriae type (main tumor occupying the fimbriae with or without confirmed microscopic invasion of the ampulla, Fig. 2 ) and undeterminable type (macroscopically undeterminable whether ampulla type or fimbriae type) of the tumor-occupying lesions. Ampulla type and fimbriae type occurred with the same frequency. A total of six patients were diagnosed with germline BRCA1 mutations and two patients with germline BRCA2 mutations among the 30 high-grade serous carcinoma cases ( Table 2 ). The mean age of patients with BRCA1 mutations was 55.2 years and 63.5 years for patients with BRCA2 mutations. However, among eight patients with BRCA1 or BRCA2 mutations, only one patient had a familial history of HBOC (pancreatic cancer) in second-degree relatives. Germline BRCA mutations were significantly more frequently observed in patients with ampulla type than fimbriae type in the present study; however, no significant differences were observed in the median age of patients, rate of complete surgery, level of p53 overexpression or overall survival (Table 3) .
Discussion
According to previous clinical surveys, patients with PFTC have a median age of approximately 60 years, and FIGO stage III disease was most frequently observed (10-13). The reported 5-year overall survival rates of patients with FIGO stage I, II, III and IV disease were 69-95, 37-75, 29-69 and 12-45% (14-16), respectively. The present study in Japanese patients with PFTC revealed that the clinicopathological features were almost identical to the respective clinical factors reported in the previous studies. However, although PFTC has been understood as a 'sausage-like' tumor, as the entire fallopian tube is dilated by the intra-tubal occurring carcinoma, our present study clearly demonstrates that PFTCs can be macroscopically divided into two types that occur at similar frequencies: the classical ampulla-occupying type (i.e. 'sausage-like' tumor) and the fimbriae-occupying type (i.e. 'pendulum-like' tumor).
Although the detailed carcinogenesis of PFTC is still unknown, research developments regarding hereditary Müllerian carcinomas have identified BRCA1 and BRCA2 as playing critical roles (17, 18) . The National Comprehensive Cancer Network (NCCN) Guidelines (19) recommend genetic testing when a woman has a familial history of breast cancer, ovarian cancer, prostate cancer, pancreatic cancer, melanoma, sarcoma, adrenocortical cancer, brain tumors, leukemia, diffuse gastric cancer, colon cancer, endometrial cancer, thyroid cancer or kidney cancer. Our present study detected 8 out of 30 patients with germline mutations of BRCA1 or BRCA2, but only 1 patient had a familial history of HBOC. This finding suggested that surveillance of BRCA mutations by familial history would be difficult in patients with PFTC compared with patients with ovarian cancer. Although present six patients with germline BRCA1 mutations were not identified as pathogenic mutations by ClinVar (20) , but it suggested new pathogenic mutations because all mutations were not missence mutation but frameshift and stop-gain mutation. Moreover, one mutation (No. 3) had been diagnosed with biliary tract cancer (21) . Furthermore, two germline BRCA2 mutations were identified as pathogenic mutation by ClinVar, and one mutation (No.7) has been previously reported in an ovarian cancer (22) . It is especially worthy of notice that in the study by Wardell et al. (21) , three patients (50%) showed the same BRCA1 mutation (Nos 2, 4 and 6). Additional studies for the detection of characteristic BRCA1 mutations in Japanese patients with PFTC are needed.
Previous studies reported that (23) 57-67% (24,25) of PFTCs exhibited p53 overexpression or p53 mutation (26) . Furthermore, recent studies proposed serous tubal intraepithelial carcinoma (STIC) was frequently observed in the fimbriae (27) (28) (29) as the precursor of ovarian and tubal high-grade serous adenocarcinoma, and nearly 92% of STICs were found to harbor p53 mutations (30) . Moreover, STIC was frequently observed in the fimbriae of patients with germline BRCA mutations (28, 29) . However, we found that germline mutations of BRCA were significantly more frequent observed in patients with ampulla type but found no significant differences in the frequency of p53 overexpression between ampulla type and fimbriae type. Therefore, we hypothesize that p53 mutations could play an important role in carcinogenesis of PFTC. Recently, our colleagues have reported that the transferrin-TfR1 axis accounts for the induction of DNA double-strand breaks in the fallopian tubal epithelium as a mechanism of DNA damage by transferrin-containing follicular fluid and/or retrograde menstrual blood (31) . These findings suggest that carcinogenetic events in both germline BRCA mutations and in mutations of the sporadic type in whole fallopian tubes could occur with equal frequency during carcinogenesis of PFTC. Generally, BRCA-mutated ovarian cancer was associated with improved overall survival and progression-free survival (32) . FIGO stage III/IV disease was significantly less frequent in patients with BRCA mutations, whereas no significant difference was observed in PFTC. The efficacy of inhibitors of poly (ADPribose) polymerase is expected to improve long-term prognosis in PFTC and in epithelial ovarian carcinoma (33, 34) . Our results show that among Japanese patients with PFTC, 26.7% presented with BRCA mutations in the germline. Furthermore, we found that p53 may be important for the carcinogenesis in fallopian tubes, independent of the specific BRCA mutation. 
